|
Manifestation
|
Total
|
NET
|
Primary necrotic chromatin
|
Secondary necrotic chromatin
|
|---|
|
n = 20/46
|
n = 41/25
|
n = 9/56
|
|---|
|
(% low/% normal)
|
(% low/% normal)
|
(% low/% normal)
|
|---|
|
Seizure
|
0
|
0/0
|
0/0
|
0/0
|
|
Psychosis
|
0
|
0/0
|
0/0
|
0/0
|
|
Organic brain syndrome
|
0
|
0/0
|
0/0
|
0/0
|
|
Visual disturbance
|
1
|
0/2.2
|
2.4/0
|
0/1.8
|
|
Lupus headache
|
0
|
0/0
|
0/0
|
0/0
|
|
Cerebrovascular accident
|
0
|
0/0
|
0/0
|
0/0
|
|
Vasculitis
|
5
|
15/4.4
|
4.9/12
|
11/7.2
|
|
Arthritis
|
8
|
10/13
|
12/12
|
11/13
|
|
Myositis
|
1
|
5/0
|
2.4/0
|
11/0*
|
|
Glomerulonephritis
| | | | |
|
Cylenduria
|
5
|
15/4.4
|
9.8/4
|
11/7
|
|
Hematuria
|
10
|
20/13
|
17/12
|
33/13
|
|
Proteinuria
|
13
|
30/15
|
22/16
|
44/16*
|
|
Pyuria
|
5
|
20/2.2*
|
9.8/4
|
22/5.4
|
|
Rash
|
10
|
15/15
|
15/16
|
11/16
|
|
Alopecia
|
9
|
20/11
|
20/4
|
22/13
|
|
Mucosal ulcers
|
8
|
15/11
|
17/4
|
22/11
|
|
Pleuritis
|
3
|
5/4.4
|
4.9/4
|
11/3.6
|
|
Pericarditis
|
0
|
0/0
|
0/0
|
0/0
|
|
Low complement
|
23
|
35/35
|
39/28
|
56/30
|
|
dsDNA antibodies
|
22
|
75/15***
|
41/20
|
67/27*
|
|
Fever
|
4
|
5/6.5
|
9.8/0*
|
0/7.1
|
|
Thrombocytopenia
|
0
|
0/0
|
0/0
|
0/0
|
|
Leukopenia
|
4
|
5/6.5
|
4.9/8
|
0/7.1
|
- Clinical manifestations during the time of sample collection were divided into groups according to their ability to degrade neutrophil extracellular traps (NETs), primary and secondary necrotic chromatin. Total patients with manifestation are indicated in the first column. For each source of DNA the total number of patients with low-versus-normal degrading ability are indicated and percent of patients with low-versus-normal degrading ability are indicated for each respective manifestation. Significance of differences were calculated using Pearson’s χ2 test: *p <0.05: and ***p <0.001; increased proportions in bold text
